251
|
Vecht CJ, Avezaat CJ, van Putten WL, Eijkenboom WM, Stefanko SZ. The influence of the extent of surgery on the neurological function and survival in malignant glioma. A retrospective analysis in 243 patients. J Neurol Neurosurg Psychiatry 1990; 53:466-71. [PMID: 2166137 PMCID: PMC1014204 DOI: 10.1136/jnnp.53.6.466] [Citation(s) in RCA: 155] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
A retrospective analysis was performed on 66 patients with anaplastic astrocytoma (AA) and 177 patients with glioblastoma multiforme (GM). The prognostic importance of age, performance status, tumour location, extent of surgery and radiation treatment was studied. Radiation therapy gave a significant improvement in survival in both AA (p less than 0.003) and GM (p less than 0.002), but was given only to patients in a good neurological condition. Both younger age (p less than 0.003), and good preoperative performance status (p less than 0.002) were associated with a longer survival in AA, but not in GM. Extensive surgery was correlated with a better immediate postoperative performance, a lower one-month mortality rate and a longer survival, in both AA and GM. There was no relationship between preoperative neurological function status and the extent of surgery. Because of the retrospective nature of this study, the conclusion is that performing extensive surgery instead of limited surgery does not lead to more deterioration in postoperative neurological function.
Collapse
Affiliation(s)
- C J Vecht
- Department of Neurosurgery, University Hospital Rotterdam, The Netherlands
| | | | | | | | | |
Collapse
|
252
|
Shibamoto Y, Yamashita J, Takahashi M, Yamasaki T, Kikuchi H, Abe M. Supratentorial malignant glioma: an analysis of radiation therapy in 178 cases. Radiother Oncol 1990; 18:9-17. [PMID: 2163064 DOI: 10.1016/0167-8140(90)90018-r] [Citation(s) in RCA: 56] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
To analyze treatment results of supratentorial malignant gliomas in the megavoltage era, all the histologic specimens were reviewed and glioblastoma multiforme (GBM) was distinguished from anaplastic astrocytoma (AA) by the presence of necrosis. Among those who had completed radiotherapy and who had been followed for at least one year, 135 GBM and 43 AA patients were found. The median survival time (MST) after operation was 12 months for GBM and 18 months for AA. The 5-year survival rate was 0.9% for GBM and 18% for AA. The size of radiation field had little influence on survival time; MST was 12 months for GBM patients treated with a local field covering tumor plus less than 2 cm margin, 12 months for those treated with a generous field (2 cm or more margin), and 13 months for those treated to whole brain. Also for AA, whole brain radiation did not prolong survival. Initial relapse of GBM and AA developed within the irradiated volume in 86% of the cases treated with a generous field. Whole brain radiation seemed useless for the treatment of malignant gliomas. Survival time appeared to be dose-dependent; MST was 10, 13, and 16 months for GBM patients who received 45-57, 57-63, and 63-72 Gy, respectively. Extensive surgical resection was associated with a better prognosis in GBM. AA patients 60 years old or older had a poorer prognosis than younger patients, but age was not a significant prognostic factor for GBM. Chemotherapy appeared to prolong survival slightly without improving long-term survival.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- Y Shibamoto
- Department of Radiology, Faculty of Medicine, Kyoto University, Japan
| | | | | | | | | | | |
Collapse
|
253
|
Abstract
This presentation will review recent data on the treatment of high grade gliomas. It deals primarily with results of radiotherapy even though several of the clinical trials to be considered also included chemotherapy. Present emphasis will be on, but not limited to, the larger prospective randomized trials conducted by various cooperative clinical groups in the United States, the United Kingdom and on the continent.
Collapse
Affiliation(s)
- G E Sheline
- Dept. of Radiation Oncology, University of California, San Francisco 94143
| |
Collapse
|
254
|
Paoletti P, Butti G, Knerich R, Gaetani P, Assietti R. Chemotherapy for malignant gliomas of the brain: a review of ten-years experience. Acta Neurochir (Wien) 1990; 103:35-46. [PMID: 2360465 DOI: 10.1007/bf01420190] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
In recent years, there has been a great improvement in the knowledge of the biological aspects of malignant gliomas of the brain. Conversely, there has been an increase of interest in the multimodal treatment of these tumours. In this review, we have analyzed the results of the several reports which have appeared in the literature that deal with the chemotherapeutic treatment of malignant gliomas. Furthermore, some areas of biological investigation that could have an impact on pharmacological therapy are discussed.
Collapse
Affiliation(s)
- P Paoletti
- Dipartimento di Chirurgia-Neurochirurgia e Centro E. Grossi-Paoletti, Università di Pavia, Italy
| | | | | | | | | |
Collapse
|
255
|
Affiliation(s)
- F Cohadon
- Clinique Universitaire de Neurochirurgie, Hôpital Pellegrin, Bordeaux, France
| |
Collapse
|
256
|
Winger MJ, Macdonald DR, Schold SC, Cairncross JG. Selection bias in clinical trials of anaplastic glioma. Ann Neurol 1989; 26:531-4. [PMID: 2684003 DOI: 10.1002/ana.410260406] [Citation(s) in RCA: 45] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
We report a retrospective analysis of survival, and attrition to a study, of patients with anaplastic glioma seen at a regional cancer center during its participation in a prospective randomized clinical trial. Median length of survival for all patients was 35 weeks. Median length of survival for study patients was 60 weeks. Study patients were not representative of all patients; they were younger and less disabled than the nonstudy patients. Survival predictions for patients with anaplastic glioma based on the results of clinical trials may be overly optimistic. Many trials study a nonrepresentative subset of patients with anaplastic glioma, excluding those who do poorly at the outset and those who have poor function.
Collapse
Affiliation(s)
- M J Winger
- Department of Oncology, University of Western Ontario, London, Canada
| | | | | | | |
Collapse
|
257
|
Winger MJ, Macdonald DR, Cairncross JG. Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma. J Neurosurg 1989; 71:487-93. [PMID: 2552044 DOI: 10.3171/jns.1989.71.4.0487] [Citation(s) in RCA: 239] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
A retrospective analysis is presented of factors affecting the length of survival of 285 consecutive adults with newly diagnosed biopsy-proven supratentorial anaplastic glioma (188 cases of glioblastoma multiforme, 76 of anaplastic astrocytoma, 11 of anaplastic mixed glioma, and 10 of anaplastic oligodendroglioma) treated at a regional cancer center from July, 1982, through December, 1987. The approach to initial therapy included maximum feasible resection and radiotherapy. The median survival time for all patients was 35 weeks. Multivariate analysis demonstrated that age, duration of symptoms, preirradiation performance status, tumor histology, accessibility to resection, extent of resection, radiotherapy, and prior low-grade glioma were significant independent variables influencing survival. The prognostic importance of age, duration of symptoms, performance status, and tumor histology are already recognized, but three "new" findings are reported. First, patients with anaplastic oligodendroglioma had the longest median survival time (278 weeks). Second, corrected for accessibility and all other variables, patients with gross total resection lived longer than those with partial resection, and patients with any degree of resection lived longer than those who underwent only a biopsy procedure. Third, patients with anaplastic glioma in whom there was a prior history of low-grade glioma lived significantly longer after the diagnosis of anaplastic glioma than did patients in whom the anaplastic glioma apparently arose de novo.
Collapse
Affiliation(s)
- M J Winger
- Department of Oncology, University of Western Ontario, London, Canada
| | | | | |
Collapse
|
258
|
Abstract
Glioblastomas and previously irradiated recurrent gliomas remain incurable. Chemotherapy is able to palliate patients by shrinking tumors, thereby improving neurological status and quality of life. Chemotherapy may also be capable of prolonging survival in some instances. The effectiveness of chemotherapy against gliomas is comparable to the efficacy of chemotherapy against many other solid tumors. When given in an adjuvant setting along with radiation postoperatively, studies suggest that the nitrosoureas, dibromodulcitol, dianhydrogalactitol, procarbazine, teniposide, dacarbazine, and cisplatin may possibly be useful, although results for many of these drugs are inconclusive. Some chemotherapy combinations also appear to be useful in an adjuvant setting, particularly BCNU plus ifosfamide, BCNU plus cisplatin, CCNU plus dibromodulcitol, and CCNU plus lonidamine. However, there is not yet conclusive evidence that combination chemotherapy is superior to single agent adjuvant chemotherapy in the treatment of gliomas. While the use of chemotherapy prior to postoperative cranial radiation is worthy of further study, it has not to date proven to be more effective than chemotherapy combined with radiation. In patients whose tumors have recurred following radiation, palliation may be achieved with the nitrosoureas, procarbazine, teniposide, and diaziquone. Cisplatin, high dose methotrexate, the interferons, and a variety of other medications also may be of use. As in the case of adjuvant chemotherapy, chemotherapy combinations for recurrent tumor have not been conclusively demonstrated to be superior to single agent treatment, although some CCNU-based combinations are of interest. Many different chemotherapy drugs have been administered by intracarotid infusion. There is a moderately high risk of serious local retinal and neurological toxicity using this approach, and efficacy has not been proven to be improved by this approach. However, further studies of intraarterial administration of chemotherapy are warranted in light of theoretical considerations, pharmacological observations of enhanced local drug concentrations, and the observation that patients who have failed the same drugs intravenously may respond when lower doses of the drug are administered intraarterially. In addition, some patients have had tumor shrinkage in the area infused while tumor has grown in other areas. Thus, while intracarotid chemotherapy must be regarded as still investigational and potentially quite toxic, further studies are indicated. High dose chemotherapy has been administered in combination with autologous bone marrow rescue. High response rates and prolonged survival durations have been reported in some instances, justifying further study despite substantial toxicity.(ABSTRACT TRUNCATED AT 400 WORDS)
Collapse
Affiliation(s)
- D J Stewart
- Ontario Cancer Treatment and Research Foundation, Ottawa, Canada
| |
Collapse
|
259
|
Tiver K. Treatment of CNS tumours with conventional radiotherapy: the importance of dose & volume factors in tumour control & CNS radiation tolerance. AUSTRALASIAN RADIOLOGY 1989; 33:15-22. [PMID: 2653295 DOI: 10.1111/j.1440-1673.1989.tb03228.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Improved localisation of central nervous system (CNS) tumours resulting from newer diagnostic imaging techniques may allow the therapeutic irradiation of smaller volumes than currently practiced with the possibility of less normal tissue injury and/or the use of higher radiation doses. The influence of radiation dose and volume on the control rates for various types of CNS tumour and on the radiation tolerance of CNS tissue is imperfectly understood. Available data on these fundamental issues in the radiation treatment of CNS tumours is reviewed.
Collapse
|
260
|
Laramore GE, Diener-West M, Griffin TW, Nelson JS, Griem ML, Thomas FJ, Hendrickson FR, Griffin BR, Myrianthopoulos LC, Saxton J. Randomized neutron dose searching study for malignant gliomas of the brain: results of an RTOG study. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1988; 14:1093-102. [PMID: 2838442 DOI: 10.1016/0360-3016(88)90384-7] [Citation(s) in RCA: 63] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
From September 1980 through January 1985, the Radiation Therapy Oncology Group (RTOG) conducted a randomized, dose-searching study testing the efficacy of a concomitant neutron boost along with whole brain photon irradiation in the treatment of malignant gliomas of the brain. Patients had to have biopsy-proven, supratentorial, anaplastic astrocytoma or glioblastoma multiforme (Nelson schema) to be eligible for the study. The whole brain photon irradiation was given at 1.5 Gy per treatment, 5 days-a-week to a total dose of 45 Gy. Two days-a-week the patients were to receive neutron boost irradiation to the tumor volume as determined on CT scans. The neutron irradiation was to be given prior to and within 3 hours of the photon irradiation on that day. The rationale for this particular treatment regime is discussed. A total of 190 evaluable patients were randomized among 6 different neutron dose levels: 3.6, 4.2, 4.8, 5.2, 5.6 and 6.0 Gyn gamma. There was no difference in overall survival among the 6 different dose levels, but for patients having less aggressive tumor histology (anaplastic astrocytoma), there was a suggestion that patients on the higher dose levels had poorer overall survival than patients on the lower dose levels and also did worse than historical photon controls. Important prognostic factors were identified using a Cox stepwise regression analysis. Tumor histology, Karnofsky performance status, and patient age were found to be related to survival while extent of surgery and neutron dose had no significant impact. Autopsies were performed on 35 patients and the results correlated with the actual neutron dose as determined by central-axis isodose calculations. At all dose levels there were some patients with both radiation damage to normal brain tissue and evidence of viable tumor. No evidence was found for a therapeutic window using this particular treatment regimen.
Collapse
Affiliation(s)
- G E Laramore
- Department of Radiation Oncology, University of Washington Hospital, Seattle 98195
| | | | | | | | | | | | | | | | | | | |
Collapse
|
261
|
Abstract
There continues to be an extensive effort to develop chemotherapeutic approaches to the treatment of malignant gliomas of the brain. In the past 5 years there have been literally hundreds of trials of new agents, combinations of old and new agents, and even new routes and approaches to the delivery of chemotherapy. In this review, the literature has been studied and the individual reports analyzed to evaluate the impact of the new findings on clinical management of the patient with malignant glioma of the brain. The major areas of progress include the addition of new drugs with varying modes of action, the use of combinations of drugs in a synergistic fashion, and the development of new routes of drug delivery. None of the advances has brought about the revolution in clinical care that is so eagerly sought, but clearly the amount of new knowledge gained by these studies helps in understanding how to use chemotherapy more effectively. Furthermore, the remarkable degree of interest and involvement in the use of chemotherapy promises that an even greater number of patients with malignant gliomas will be considered for vigorous and enthusiastic clinical management programs even if chemotherapy itself is not the key modality in the treatment of a specific patient.
Collapse
Affiliation(s)
- P L Kornblith
- Department of Neurological Surgery, Albert Einstein College of Medicine, New York, New York
| | | |
Collapse
|
262
|
Abstract
Eighty two adult patients with histologically proven cerebral astrocytomas of grades I to IV received post-operative radiotherapy at Westmead Hospital between January 1980 and February 1985. The extent of surgery consisted of biopsy alone in 44%, subtotal tumour resection in 48%, and "complete" tumour removal in 8%. Seventy one patients completed a course of megavoltage irradiation, the majority having received a tumour dose of at least 60 Gy. Patients who underwent surgical resection (complete or incomplete) had a greater median survival (14 months) than those undergoing biopsy (8 months), but the difference was not statistically significant (p = 0.08). By grade, the difference reached statistical significance only for grade III tumours (p = 0.015). Patients with high grade tumours had a significantly lower survival than those patients with tumours of low grade. Median survival for patients with grades I and II, III and IV tumours was 42.0, 12.0 and 7.0 months, respectively. After adjustment for grade, various dosage levels (less than 60, 60 or greater than 60 Gy) did not significantly affect survival, although there was a trend towards improved median survival with higher doses in grade III tumours. Older patients (greater than 45 years) had a significantly lower median survival (25 months) than younger patients (8 months) (p less than 0.0001). When included in a multivariate analysis, the extent of surgery did not significantly influence survival, but increasing tumour grade and increasing age were significant adverse prognostic factors.
Collapse
|
263
|
Foy PM, Shaw MD, Williams IR, Chadwick DW. Neurological and neurosurgical approaches in the management of malignant brain tumours. BMJ 1987; 294:372. [PMID: 3028546 PMCID: PMC1245375 DOI: 10.1136/bmj.294.6568.372-a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
|
264
|
Lawson A, McMurray J, Northridge DB. Association between liberalization of Scotland's liquor licensing laws and admissions for self poisoning. BMJ : BRITISH MEDICAL JOURNAL 1987; 294:371-2. [PMID: 3101883 PMCID: PMC1245373 DOI: 10.1136/bmj.294.6568.371-c] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|
265
|
Morgan A, Jeffcoate W. Manpower. West J Med 1987. [DOI: 10.1136/bmj.294.6568.372] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
266
|
Bishop NL. What is a good GP? West J Med 1987. [DOI: 10.1136/bmj.294.6564.123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
267
|
Fadul CE, Shapiro WR, Posner JB. Neurological and neurosurgical approaches in the management of malignant brain tumours. West J Med 1987. [DOI: 10.1136/bmj.294.6564.123-c] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
268
|
|
269
|
Thomas DGT, Darling JL, Tobias JS, Souhami RL, Paul EA. Neurological and neurosurgical approaches in the management of malignant brain tumours. BRITISH MEDICAL JOURNAL 1987; 294:123-4. [PMID: 3105651 PMCID: PMC1245135 DOI: 10.1136/bmj.294.6564.123-b] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Affiliation(s)
- D G T Thomas
- Neuro-oncology Section, Gough-Cooper Department of Neurological Surgery, Institute of Neurology, National Hospital, London WC1N 3BG
- Department of Radiotherapy and Oncology, University College Hospital, London WC1E 6AU
- Department of Community Medicine, St Thomas's Hospital, London SE1 7EH
| | - J L Darling
- Neuro-oncology Section, Gough-Cooper Department of Neurological Surgery, Institute of Neurology, National Hospital, London WC1N 3BG
- Department of Radiotherapy and Oncology, University College Hospital, London WC1E 6AU
- Department of Community Medicine, St Thomas's Hospital, London SE1 7EH
| | - J S Tobias
- Neuro-oncology Section, Gough-Cooper Department of Neurological Surgery, Institute of Neurology, National Hospital, London WC1N 3BG
- Department of Radiotherapy and Oncology, University College Hospital, London WC1E 6AU
- Department of Community Medicine, St Thomas's Hospital, London SE1 7EH
| | - R L Souhami
- Neuro-oncology Section, Gough-Cooper Department of Neurological Surgery, Institute of Neurology, National Hospital, London WC1N 3BG
- Department of Radiotherapy and Oncology, University College Hospital, London WC1E 6AU
- Department of Community Medicine, St Thomas's Hospital, London SE1 7EH
| | - E A Paul
- Neuro-oncology Section, Gough-Cooper Department of Neurological Surgery, Institute of Neurology, National Hospital, London WC1N 3BG
- Department of Radiotherapy and Oncology, University College Hospital, London WC1E 6AU
- Department of Community Medicine, St Thomas's Hospital, London SE1 7EH
| |
Collapse
|
270
|
Bignardi M, Bertoni F. Radiation treatment with twice a day fractionation versus conventional fractionation in high grade astrocytoma. A retrospective study. Acta Oncol 1987; 26:441-5. [PMID: 3446243 DOI: 10.3109/02841868709113715] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
A consecutive series of 73 patients with high grade astrocytoma treated by surgery and postoperative radiotherapy was analysed. A total tumour dose of 60 Gy was delivered with either 2 Gy daily fractions (24 patients) or twice a day 1.5 Gy fractions, with a 4-hour-interval (49 patients). The analysis of survival with respect to patient variables showed that age and performance status were significant prognostic factors. As the type of fractionation was not randomly assigned, the comparison between the conventional schedule (CF) and the multifractionated schedule (MFD) was performed by means of a multivariate analysis adjusting for basic prognostic factors; CF proved to be significantly superior to MFD. The possible reasons for the disagreement between our results and the theoretical expectations in favour of MFD are discussed.
Collapse
Affiliation(s)
- M Bignardi
- Department of Radiotherapy, Ospedale di Circolo, Varese, Italy
| | | |
Collapse
|
271
|
Greitz T, Lax I, Bergström M, Arndt J, Berggren BM, Blomgren H, Boëthius J, Lindqvist M, Ribbe T, Steiner L. Stereotactic radiation therapy of intracranial lesions. Methodologic aspects. ACTA RADIOLOGICA. ONCOLOGY 1986; 25:81-9. [PMID: 3012962 DOI: 10.3109/02841868609136383] [Citation(s) in RCA: 35] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
A technique for stereotactic radiation therapy of cerebral tumours and arteriovenous malformations using a linear accelerator (6 MV photons) is proposed. Treatment relies on a fixation system that permits a precise use of the coordinates estimated at stereotactic angiography or stereotactic computed tomography. The field of treatment can be exactly outlined in the CT images during repeat examinations, thus facilitating the recognition of changes induced by radiation. The system also allows the extent of the arteriovenous malformation, as seen at angiography, to be accurately traced in the CT sections thus enabling evaluation of possible radiation damage to surrounding brain structures. The precision of the method as well as its hypothetical merits and disadvantages are discussed. The number of patients treated is still small and the follow-up time is too short in the majority of cases to allow definite conclusions. Examples of preliminary results are given.
Collapse
|
272
|
Hatlevoll R, Lindegaard KF, Hagen S, Kristiansen K, Nesbakken R, Torvik A, Ganz JC, Mella O, Rosengren B, Ringkjöb R. Combined modality treatment of operated astrocytomas grade 3 and 4. A prospective and randomized study of misonidazole and radiotherapy with two different radiation schedules and subsequent CCNU chemotherapy. Stage II of a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1985; 56:41-7. [PMID: 2988737 DOI: 10.1002/1097-0142(19850701)56:1<41::aid-cncr2820560108>3.0.co;2-w] [Citation(s) in RCA: 50] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
A prospective and randomized trial has been performed in order to evaluate combined modality therapy in patients with astrocytomas grade 3 and 4. Follow-up information is available on 244 patients. One half of the series received radiation therapy twice a week (40.00 Gy/5 weeks), the other half five times a week (50.00 Gy/5 weeks). Misonidazole 1.2 g/m2 was given orally to one half of the patients in the first radiation treatment group 3 1/2 to 4 hours before the treatment. The other half received placebo. The second radiation treatment group was also divided in two halves, one receiving 0.48 g/m2 misonidazole and the other placebo 3 1/2 to 4 hours before radiation. The randomization also included a subdivision of the material into eight groups of which four were given CCNU and four no chemotherapy, beginning 3 months after operation. The dose of CCNU was 120 mg/m2 body surface every 6 weeks. All eight treatment groups showed practically identical periods of median survival, and no statistically significant differences were observed with regard to performance status, side effects, or complications. Another dosage and timing of misonidazole administration in relation to the irradiation schedule, and a consideration of effects of concomitant drugs like dexamethasone and phenytoin are discussed.
Collapse
|
273
|
Kelly KA, Kirkwood JM, Kapp DS. Glioblastoma multiforme: pathology, natural history and treatment. Cancer Treat Rev 1984; 11:1-26. [PMID: 6203642 DOI: 10.1016/0305-7372(84)90014-8] [Citation(s) in RCA: 47] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
274
|
Abstract
Chemotherapy of malignant glioma has been discussed in relation to recent advances in experimental and clinical studies. It is now obvious that chemotherapy is of increasing importance in the multidisciplinary treatment of malignant gliomas. Survival time of patients was prolonged by intensive and prolonged chemotherapy and by second treatment upon tumour recurrence. Further progress of chemotherapy will be gained by the progressive accumulation of all experiences, however small, in all the varied routes of approach.
Collapse
|
275
|
Abstract
A logical inference from the recent reports indicating that malignant brain tumors are composed of a heterogeneous cell population is that combination chemotherapy will be required for effective brain tumor control. For several years we have been investigating the use of Bleomycin as an agent to be used in conjunction with radiation therapy and a nitrosourea compound. Since systemically administered Bleomycin does not cross the blood-brain-barrier and has significant toxicity when used parenterally in high doses, we have studied the use of smaller doses of Bleomycin injected directly into the brain tumor cavity. Such an intracerebral dose was more effective in prolonging survival of rats burdened with experimental 9L gliosarcomas than an intravenous dose that is 25 times as great. The combination of intracerebrally administered Bleomycin and radiation therapy was more effective than either modality alone. Furthermore, the combination of Bleomycin delivered intracerebrally and BCNU given systemically was more effective than either agent used alone. Finally, in a Phase I clinical of Bleomycin given via an Ommaya reservoir to eight patients with recurrent malignant brain tumors, we have demonstrated that individual doses of up to 7.5 units and cumulative doses of up to 255 units can be administered without significant toxicity.
Collapse
|
276
|
Eyre HJ, Quagliana JM, Eltringham JR, Frank J, O'Bryan RM, McDonald B, Rivkin SE. Randomized comparisons of radiotherapy and CCNU versus radiotherapy, CCNU plus procarbazine for the treatment of malignant gliomas following surgery. A Southwest Oncology Group Report. J Neurooncol 1983; 1:171-7. [PMID: 6088713 DOI: 10.1007/bf00165600] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
One hundred and fifteen eligible patients with histologically verified malignant gliomas (astrocytoma grade III-IV) were randomized to receive either radiotherapy 6 000 rads/7 week plus CCNU 130 mg/M2 every 6 weeks (treatment 1) or radiotherapy 6 000 rads/7 weeks plus CCNU 75 mg/M2 day 1 plus procarbazine 100 Mg/m2 days 1-14 every 6 weeks (treatment 2) within 4 weeks following surgical resection. The response rates showed no statistically significant differences between treatment 1 CR/PR - 24/17% and treatment 2 CR/PR - 14/14% (P-value = 0.31). The median survival was also not significantly different: 55 and 50 weeks for treatments 1 and 2, respectively. The most important prognostic parameter identified was age with younger patients showing higher response rates and longer survival. Patients' performance status was also a useful prognostic parameter for response and survival. Neither the extent of surgical resection nor the tumor grade correlated significantly with the outcome. Further studies are needed to identify active chemotherapeutic agents for the treatment of brain tumors.
Collapse
|